Journal of Diabetes and Its Complications
Volume 24, Issue 2 , Pages 79-83 , March 2010

Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations

  • Raffaele Marfella

      Affiliations

    • Department of Geriatrics and Metabolic Diseases Second University of Naples, Naples, Italy
    • Corresponding Author InformationCorresponding author. 80138 Napoli, Italy. Tel.: +39 081 5665110; fax: +39 081 5096142.
    • ,
  • Michelangela Barbieri

      Affiliations

    • Department of Geriatrics and Metabolic Diseases Second University of Naples, Naples, Italy
    • ,
  • Rodolfo Grella

      Affiliations

    • Department of Geriatrics and Metabolic Diseases Second University of Naples, Naples, Italy
    • ,
  • Maria Rosaria Rizzo

      Affiliations

    • Department of Geriatrics and Metabolic Diseases Second University of Naples, Naples, Italy
    • ,
  • Giovanni Francesco Nicoletti

      Affiliations

    • Plastic and Reconstructive Surgery, Second University of Naples, Naples, Italy
    • ,
  • Giuseppe Paolisso

      Affiliations

    • Department of Geriatrics and Metabolic Diseases Second University of Naples, Naples, Italy

Received 14 September 2008 ,Revised 4 December 2008 ,Accepted 21 January 2009.

References 

  1. Ahrén B. Dipeptidyl peptidase-4 inhibitors: Clinical data and clinical implications. Diabetes Care. 2007;30:1344–1350
  2. Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–1705
  3. Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism. 2006;91:4612–4619
  4. Klein R. Hyperglycemia and microvascular disease in diabetes. Diabetes Care. 1995;18:258–268
  5. Mari A, Sallas WM, He YL, Watson C, Ligueros-Seylan M, Dunning BE, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism. 2005;90:4888–4894
  6. Monnier L, Lapinski H, Colette C. Contribution of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA1c. Diabetes Care. 2003;26:881–885
  7. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295:1681–1687
  8. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Taylor WF, Cremer GM, et al. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes. 1970;19:644–655
  9. Service FJ, O'Brien PC, Rizza RA. Measurements of glucose control. Diabetes Care. 1987;10:225–237
  10. Stratton IM, Alder AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. UK Prospective Diabetes Study Group. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ. 2000;321:405–412

PII: S1056-8727(09)00007-5

doi: 10.1016/j.jdiacomp.2009.01.004

Journal of Diabetes and Its Complications
Volume 24, Issue 2 , Pages 79-83 , March 2010

Article Tools

* Image Usage & Resolution